MediLink Therapeutics
PrivateLast Round
Series B
Mar 14, 2022
Total Funding Raised
$120M
Company Overview
MediLink Therapeutics operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series B round in March 2022.
MediLink Therapeutics is a biopharmaceutical company that develops innovative antibody-drug conjugates (ADC) for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MediLink Therapeutics Comparables
Compare MediLink Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Duality Biotherapeutics Inc | 93% | |
| Aimed Bio Inc. | 82% | |
| LigaChem Biosciences | 79% |
For institutional investors. Book with your work email.
MediLink Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 14, 2022 | ||||
| Series A | Mar 1, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MediLink Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HighLight Capital | Series B |
| Loyal Valley Capital | Series B, Series A |
| Highlight Capital | Series B |
| LYFE Capital | Series B |
| Legend Capital | Series B |
| Qiming Venture Partners | Series B, Series A |
| Panacea Venture Healthcare | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 76% MoM.
- Jul 1, 2025
Dr. Weichang Zhou appointed as new CTO.
For institutional investors. Book with your work email.
MediLink Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MediLink Therapeutics's valuation, stock price, and market status.
Is MediLink Therapeutics a public or private company?
MediLink Therapeutics is a private company.
What is the current stock price of MediLink Therapeutics?
MediLink Therapeutics is a private company, so its shares have no public market price. Caplight tracks MediLink Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MediLink Therapeutics worth (valuation)?
Valuation information for MediLink Therapeutics is not publicly available.
Can I buy MediLink Therapeutics stock?
MediLink Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MediLink Therapeutics's last funding round?
MediLink Therapeutics's most recent funding round was Series B on March 14, 2022.
Who are the main investors in MediLink Therapeutics?
Key investors in MediLink Therapeutics include Loyal Valley Capital, LYFE Capital, Qiming Venture Partners, Apricot Capital, Apricot Capital.
Will MediLink Therapeutics IPO soon?
No public IPO plans have been announced for MediLink Therapeutics.
How can I track MediLink Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in MediLink Therapeutics's shares on secondary markets.